Research & Development
-
Justin Sullivan via Getty Images
Will Walgreens’ store closures derail its clinical trial aims?
Despite a plan to shutter 1,200 stores, the company’s chief clinical trials officer said the pharmacy juggernaut remains committed to drug research.
By Meagan Parrish • Nov. 22, 2024 -
George Clerk via Getty Images
Pfizer, under pressure to change, names oncology head as new R&D chief
Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.
By Kristin Jensen • Nov. 21, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
Permission granted by Merck & Co.
Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals
A subcutaneous version of Merck’s Keytruda was as effective as the infused version in a late-stage study, but the company won’t be the first to market.
By Michael Gibney • Nov. 21, 2024 -
Brad Penner/Imagn Images/Reuters
The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate.
The company is looking to score an FDA nod for its investigational therapy that targets a molecule linked to Guillain-Barré syndrome and other autoimmune diseases.
By Alexandra Pecci • Nov. 19, 2024 -
Permission granted by AbbVie
What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
AbbVie’s head of R&D cures has lofty ambitions to end diseases like HIV through a community of researchers that work as one.
By Michael Gibney • Nov. 19, 2024 -
Erik S. Lesser via Getty Images
Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug
Merck’s acquisition of Modifi Biosciences bucks common M&A trends in pharma.
By Kelly Bilodeau • Nov. 18, 2024 -
Stock via Getty Images
The first MASH drug could open the door for others — including GLP-1s
With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.
By Amy Baxter • Nov. 18, 2024 -
Stock via Getty Images
Where are they now? 4 biotechs that soared then crashed during the pandemic
How Novavax and others have restructured and trudged forward after their COVID-era high.
By Meagan Parrish • Nov. 15, 2024 -
Stock via Getty Images
Pharma’s grip on cancer R&D is having unintended consequences
A pair of studies paint a complicated picture of funding and missed research opportunities.
By Alexandra Pecci • Nov. 12, 2024 -
Stock via Getty Images
Spravato is just the beginning in a new wave of depression meds
Psychiatry is getting more targeted as drugmakers develop a new range of treatments for depression.
By Meagan Parrish • Nov. 11, 2024 -
Jacob Bell/PharmaVoice
An RNAi renaissance is creating a new generation of startups
Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.
By Gwendolyn Wu • Nov. 7, 2024 -
Stock via Getty Images
A diabetes drug, twice rejected, stumbles again — but its developer persists
After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 diabetes therapy.
By Amy Baxter • Nov. 6, 2024 -
Permission granted by Rallybio
Two former Alexion leaders fight through a tough market to maintain a rare disease biotech
Rallybio is headed into a mid-stage trial with enough cash through 2026, but the cyclical market has made the journey difficult.
By Michael Gibney • Nov. 5, 2024 -
Permission granted by Sernova
ProfileCEO with type 1 diabetes works to deliver ‘world’s first’ functional cure
Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.
By Alexandra Pecci • Nov. 5, 2024 -
Stock via Getty Images
Pharma takes aim at a wily foe — the Epstein-Barr virus
The pernicious and widespread virus has been linked to a range of diseases including MS and long COVID.
By Kelly Bilodeau • Nov. 4, 2024 -
Spencer Platt / Staff via Getty Images
Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s
Pfizer’s second-to-market goals for its oral GLP-1 drugs underscore big opportunities in the space.
By Amy Baxter • Nov. 4, 2024 -
Stock via Getty Images
A sickle cell cure exists. But patients need more than just gene therapy.
Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier.
By Alexandra Pecci • Nov. 1, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Cancer Care Visionaries
Leaders who envision a world without cancer through oncology innovation.
By Michael Gibney • Nov. 1, 2024 -
Getty Images via Getty Images
Big Pharma earnings hang hope on the next generation of blockbusters
Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.
By Michael Gibney • Oct. 31, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Clinical Trial Pros
Experts raising the bar in clinical trial design and collaboration.
By Amy Baxter • Oct. 31, 2024 -
Photo illustration: Industry Dive; Getty Images via Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Cell and Gene Therapy Pioneers
Leaders molding the cutting-edge cell and gene therapy field into tomorrow's cures.
By Michael Gibney • Oct. 30, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Rare Disease Warriors
Pharma pros driving drug development and access for patients with high unmet needs.
By Meagan Parrish • Oct. 29, 2024 -
eranicle via Getty Images
Q&AHow AZ’s respiratory wins are ramping up for a bigger prize in COPD
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.
By Michael Gibney • Oct. 29, 2024 -
Stock via Getty Images
On the front lines of the superbug war, new treatments can’t arrive soon enough
As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.
By Kelly Bilodeau • Oct. 28, 2024 -
Permission granted by Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Biotech Pathfinders
Leaders solving biology's toughest puzzles and driving innovation forward.
By Michael Gibney • Oct. 23, 2024
